Characteristics and clinical outcome of patients who developed an immune response against transgene products
| Patient no. . | CD4+ cells at infusion, cells/μL . | Time between HSCT and infusion, wk . | Multiple infusions . | Clinical outcome after TK-DLI . | Clinical outcome after immunization against transgenes (wk) . |
|---|---|---|---|---|---|
| 2 | 234 | 53 | Y | PR | NR |
| 7 | 107 | 73 | Y | CR | CR (49) |
| 8 | 60 | 24 | Y | CR | CR (269) |
| 16 | 270 | 67 | Y | CR | CR (328) |
| 17 | 442 | 52 | N | CR | CR (100) |
| 20 | 656 | 278 | Y | PR | NR |
| 21 | 200 | 120 | N | CR | CR (238) |
| Average for nonimmunized patients | 96 | 36 | 4/11 Y | NA | NA |
| Patient no. . | CD4+ cells at infusion, cells/μL . | Time between HSCT and infusion, wk . | Multiple infusions . | Clinical outcome after TK-DLI . | Clinical outcome after immunization against transgenes (wk) . |
|---|---|---|---|---|---|
| 2 | 234 | 53 | Y | PR | NR |
| 7 | 107 | 73 | Y | CR | CR (49) |
| 8 | 60 | 24 | Y | CR | CR (269) |
| 16 | 270 | 67 | Y | CR | CR (328) |
| 17 | 442 | 52 | N | CR | CR (100) |
| 20 | 656 | 278 | Y | PR | NR |
| 21 | 200 | 120 | N | CR | CR (238) |
| Average for nonimmunized patients | 96 | 36 | 4/11 Y | NA | NA |
The reported parameters were measured at the infusion inducing immunity for patients 2, 7, 8, and 16, and at the time of the first infusion for all the other patients. Clinical outcome after TK-DLI was measured at the time of detection of immunization against transgene products.
NA indicates not applicable. Additional abbreviations are explained in Table 1.